Related Experiment Videos
Phase I study of oral mitomycin C
Cancer Treatment Reports
|November 1, 1976
Abstract:
This study demonstrates that the gastrointestinal absorption of oral mitomycin C is variable and that myelosuppression correlates most closely with the peak serum concentration. The probable maximal-tolerated dose of oral mitomycin C is 45-50 mg/m2.
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Transient dilated cardiomyopathy phenotype and positive Bartonella serology in a cat.
Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology·2025
Primary care triaging of head and neck cancer referrals using the head and neck cancer risk calculator version 2: impact on a tertiary head and neck service.
The Journal of laryngology and otology·2022
Developing and testing a case-management intervention to support the return to work of health care workers with common mental health disorders.
Journal of public health (Oxford, England)·2022
Do initiation rites hasten sexual debut among adolescent girls? A longitudinal analysis from Ghana.
Culture, health & sexuality·2022
Cisplatin as a first-line treatment in T2 and T3 bladder carcinoma.
Cancer treatment reports·1987
IV melphalan in children.
Cancer treatment reports·1987
Interactions of methotrexate and cyclophosphamide with the pharmacokinetics of 5-fluorouracil in an animal model.
Cancer treatment reports·1987
Phase II trial of rDNA alfa 2b interferon in patients with malignant carcinoid tumor.
Cancer treatment reports·1987
Doxorubicin distribution in human breast cancer.
Cancer treatment reports·1987
Phase I study of echinomycin.
Cancer treatment reports·1987
A Rat Excisional Wound Model for Investigating Therapeutics in Critical-Size Skin Wounds.
Journal of visualized experiments : JoVE·2026
Current evidence across the treatment spectrum of adrenocortical carcinoma: a comprehensive scoping review.
Endocrine oncology (Bristol, England)·2026
Combination of Palladium Nanoparticles and Tubastatin-A Potentiates Apoptosis in Human Breast Cancer Cells: A Novel Therapeutic Approach for Cancer [Retraction].
International journal of nanomedicine·2026